[go: up one dir, main page]

CZ20012001A3 - Směs obsahující makrolidy, farmaceutický přípravek obsahující tuto směs a způsob stabilizace makrolidů - Google Patents

Směs obsahující makrolidy, farmaceutický přípravek obsahující tuto směs a způsob stabilizace makrolidů

Info

Publication number
CZ20012001A3
CZ20012001A3 CZ20012001A CZ20012001A CZ20012001A3 CZ 20012001 A3 CZ20012001 A3 CZ 20012001A3 CZ 20012001 A CZ20012001 A CZ 20012001A CZ 20012001 A CZ20012001 A CZ 20012001A CZ 20012001 A3 CZ20012001 A3 CZ 20012001A3
Authority
CZ
Czechia
Prior art keywords
macrolides
mixture
comprised
pharmaceutical preparation
stabilization method
Prior art date
Application number
CZ20012001A
Other languages
English (en)
Other versions
CZ303006B6 (cs
Inventor
François Navarro
Samuel Petit
Guy Stone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ20012001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CZ20012001A3 publication Critical patent/CZ20012001A3/cs
Publication of CZ303006B6 publication Critical patent/CZ303006B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CZ20012001A 1998-12-07 1999-12-06 Zpusob stabilizace 40-O-(2-hydroxy)ethylrapamycinu, který má imunosupresivní vlastnosti, a smes obsahující 40-O-(2-hydroxy)ethylrapamycin a antioxidant CZ303006B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (2)

Publication Number Publication Date
CZ20012001A3 true CZ20012001A3 (cs) 2001-09-12
CZ303006B6 CZ303006B6 (cs) 2012-02-22

Family

ID=26314797

Family Applications (2)

Application Number Title Priority Date Filing Date
CZ20050170A CZ302210B6 (cs) 1998-12-07 1999-12-06 Nesolvatovaná@krystalická@forma@@@@O@@@@hydroxyethyl@@rapamycinu@@zpusob@její@prípravy@a@farmaceutická@kompozice@obsahující@tuto@krystalickou@formu
CZ20012001A CZ303006B6 (cs) 1998-12-07 1999-12-06 Zpusob stabilizace 40-O-(2-hydroxy)ethylrapamycinu, který má imunosupresivní vlastnosti, a smes obsahující 40-O-(2-hydroxy)ethylrapamycin a antioxidant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CZ20050170A CZ302210B6 (cs) 1998-12-07 1999-12-06 Nesolvatovaná@krystalická@forma@@@@O@@@@hydroxyethyl@@rapamycinu@@zpusob@její@prípravy@a@farmaceutická@kompozice@obsahující@tuto@krystalickou@formu

Country Status (38)

Country Link
US (5) US6605613B2 (cs)
EP (4) EP1137439B2 (cs)
JP (3) JP3805625B2 (cs)
KR (2) KR20060096477A (cs)
CN (2) CN1876657B (cs)
AR (3) AR026102A1 (cs)
AT (1) ATE365051T1 (cs)
AU (1) AU759219B2 (cs)
BE (1) BE1012869A3 (cs)
BR (1) BR9915986A (cs)
CA (3) CA2651609A1 (cs)
CO (1) CO4980847A1 (cs)
CY (1) CY1106870T1 (cs)
CZ (2) CZ302210B6 (cs)
DE (1) DE69936352T3 (cs)
DK (1) DK1137439T4 (cs)
ES (1) ES2288033T5 (cs)
FR (1) FR2786771B1 (cs)
GB (2) GB9826882D0 (cs)
HK (1) HK1038889B (cs)
HU (2) HU230174B1 (cs)
ID (1) ID29250A (cs)
IL (1) IL143092A0 (cs)
IT (1) IT1319701B1 (cs)
MY (2) MY127579A (cs)
NO (2) NO332698B1 (cs)
NZ (2) NZ511936A (cs)
PE (1) PE20001333A1 (cs)
PL (2) PL208854B1 (cs)
PT (1) PT1137439E (cs)
RU (1) RU2243769C2 (cs)
SG (1) SG151072A1 (cs)
SI (1) SI1137439T2 (cs)
SK (2) SK287325B6 (cs)
TR (2) TR200201428T2 (cs)
TW (2) TWI248938B (cs)
WO (1) WO2000033878A2 (cs)
ZA (1) ZA200104360B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
EP1474404A4 (en) 2002-02-13 2006-01-11 Biogal Gyogyszergyar PROCESS FOR EXTRACTION OF A BIOLOGICAL MATERIAL
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
TR200500302T3 (tr) 2003-03-31 2005-04-21 Biogal Gyogyszergyar Rt. Makrolidlerin kristalizasyonu ve saflaştırılması.
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
ATE378345T1 (de) 2003-07-24 2007-11-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur aufreinigung von makroliden
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005056103A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
KR20070083839A (ko) * 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
AU2006322030A1 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
KR20080077989A (ko) * 2005-12-20 2008-08-26 와이어쓰 약물의 불순물 조절을 통한 ｃｃｉ-779 제형의 안정성 조절
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
EP2576590A1 (en) * 2010-06-07 2013-04-10 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
WO2012017449A1 (en) * 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (cs) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
US10383860B2 (en) 2015-07-28 2019-08-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
WO2017204215A1 (ja) 2016-05-27 2017-11-30 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
CN119431400A (zh) * 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) * 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0593227B1 (en) 1992-10-13 2006-03-22 Wyeth Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
CA2219659C (en) * 1995-06-09 2008-03-18 Novartis Ag Rapamycin derivatives
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6239124B1 (en) * 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
JP2001511780A (ja) 1997-02-04 2001-08-14 アボツト・ラボラトリーズ 鎮痛性非経口リポソーム配合物

Also Published As

Publication number Publication date
TWI248938B (en) 2006-02-11
DK1137439T4 (da) 2012-03-19
ES2288033T3 (es) 2007-12-16
ZA200104360B (en) 2002-01-16
KR20010101128A (ko) 2001-11-14
EP2269651A3 (en) 2011-03-09
CO4980847A1 (es) 2000-11-27
MY120594A (en) 2005-11-30
CA2732620C (en) 2013-08-06
NO20121113L (no) 2001-05-16
JP2005200429A (ja) 2005-07-28
PL348333A1 (en) 2002-05-20
EP1743657A3 (en) 2007-03-28
TWI270550B (en) 2007-01-11
EP1743657A2 (en) 2007-01-17
NO20012424D0 (no) 2001-05-16
RU2243769C2 (ru) 2005-01-10
TW200540179A (en) 2005-12-16
FR2786771A1 (fr) 2000-06-09
ITMI992520A0 (it) 1999-12-02
JP5043308B2 (ja) 2012-10-10
PL196627B1 (pl) 2008-01-31
PT1137439E (pt) 2007-09-25
SG151072A1 (en) 2009-06-29
CN1374872A (zh) 2002-10-16
SI1137439T1 (sl) 2008-06-30
ATE365051T1 (de) 2007-07-15
US20080161334A1 (en) 2008-07-03
CN1261163C (zh) 2006-06-28
AU759219B2 (en) 2003-04-10
PE20001333A1 (es) 2000-12-12
JP2002531527A (ja) 2002-09-24
AR026102A1 (es) 2003-01-29
IL143092A0 (en) 2002-04-21
SI1137439T2 (sl) 2012-05-31
JP5165199B2 (ja) 2013-03-21
US20020032213A1 (en) 2002-03-14
US20030191148A1 (en) 2003-10-09
US20090270441A1 (en) 2009-10-29
JP3805625B2 (ja) 2006-08-02
US20050107418A1 (en) 2005-05-19
CA2351580C (en) 2012-03-20
ES2288033T5 (es) 2012-04-10
NO332698B1 (no) 2012-12-10
EP1137439A2 (en) 2001-10-04
WO2000033878A2 (en) 2000-06-15
ITMI992520A1 (it) 2001-06-02
EP2279751A2 (en) 2011-02-02
CZ302210B6 (cs) 2010-12-22
GB9826882D0 (en) 1999-01-27
HUP0104489A2 (hu) 2002-03-28
PL208854B1 (pl) 2011-06-30
IT1319701B1 (it) 2003-10-27
MY127579A (en) 2006-12-29
NO20012424L (no) 2001-05-16
TR200101416T2 (tr) 2002-01-21
KR100695834B1 (ko) 2007-03-19
US6605613B2 (en) 2003-08-12
CA2351580A1 (en) 2000-06-15
BE1012869A3 (fr) 2001-04-03
HK1038889A1 (en) 2002-04-04
CN1876657A (zh) 2006-12-13
GB9904934D0 (en) 1999-04-28
HUP0104489A3 (en) 2004-05-28
FR2786771B1 (fr) 2002-12-27
NZ527781A (en) 2004-11-26
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
DE69936352T3 (de) 2012-05-03
EP1137439B2 (en) 2011-11-23
HU230174B1 (hu) 2015-09-28
HU228939B1 (en) 2013-07-29
AU1657300A (en) 2000-06-26
CA2651609A1 (en) 2000-06-15
BR9915986A (pt) 2001-09-04
US7741338B2 (en) 2010-06-22
CN1876657B (zh) 2013-01-09
AR054444A2 (es) 2007-06-27
WO2000033878A3 (en) 2000-11-02
NO334612B1 (no) 2014-04-22
HK1038889B (en) 2008-01-25
CZ303006B6 (cs) 2012-02-22
NZ511936A (en) 2003-10-31
EP1137439B1 (en) 2007-06-20
US6852729B2 (en) 2005-02-08
SK286688B6 (sk) 2009-03-05
TR200201428T2 (tr) 2002-12-23
DE69936352T2 (de) 2008-02-14
JP2006111637A (ja) 2006-04-27
DE69936352D1 (de) 2007-08-02
SK287325B6 (sk) 2010-07-07
ID29250A (id) 2001-08-16
US7572804B2 (en) 2009-08-11
US7297703B2 (en) 2007-11-20
KR20060096477A (ko) 2006-09-11
EP2269651A2 (en) 2011-01-05
EP2279751A3 (en) 2011-02-16
SK7662001A3 (en) 2001-12-03
CA2732620A1 (en) 2000-06-15
AR048073A2 (es) 2006-03-29

Similar Documents

Publication Publication Date Title
CZ20012001A3 (cs) Směs obsahující makrolidy, farmaceutický přípravek obsahující tuto směs a způsob stabilizace makrolidů
HUP0301192A3 (en) Pharmaceutical composition of topiramate and process for its preparation
HUP0001094A3 (en) Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone
HUP0103357A3 (en) Halichondrin analogs and methods of their use and preparation
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
HUP0100568A3 (en) 11beta-halogen-7alpha-substituted estratrienes, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
PL311871A1 (en) Novel derivatives of erythromycin, method of obtaining them and drugs containing such derivatives
HUP0001607A3 (en) Thienopyrimidine derivatives, pharmaceutical compositions containing them, process for their preparation and use of the compounds
PL330841A1 (en) Benzosulphonic derivatives, method of obtaining them and therapeutic agents containing such derivatives
AP2003002744A0 (en) Heparin-derived polysaccharide mixtures preparation method and pharmaceutical compositions containing same
ZA984266B (en) Pharmaceutical composition and process of preparation
IL133101A0 (en) New derivatives of erythromycin their preparation and their use as medicaments
PL352293A1 (en) Derivatives of purine, method of making same and pharmaceutical compositions containing these derivatives
HUP9901326A3 (en) Benzopyran derivatives having leukotriene-antagonistic action, pharmaceutical compositions containing these compounds, process for the preparation and use of these compounds and compositions
GR3034020T3 (en) Maltitol composition and its process of preparation
HUP9904210A3 (en) Analogues of camptothecin,their application as medicine and pharmaceutical compositions containing them
HUP0101098A3 (en) Streptogramin derivatives, process for preparation thereof and compositions containing same
SI1049706T1 (en) New pentasaccharides, their methods of production and pharmaceutical compositions containing same
CZ92295A3 (en) Boronpeptide derivatives, process of their preparation and pharmaceutical composition containing thereof
HU228271B1 (en) Compositions for treating soils, method of preparation and use thereof
AU2001252741A1 (en) Pharmaceutical composition containing itraconazole with gastric ph-independentlyimproved solubility and preparation method thereof
SG121739A1 (en) Stabilized protein crystals, formulations containing them and methods of making them
PL340381A1 (en) Novel 19-norsteroids substituted at position 11beta, method of obtaining them, intermediate compounds used in that method, their application as drugs and pharmacological compositions containing them
GB2308364B (en) Process for the preparation of 3-isothiazolone mixture and composition comprising the mixture
PL331444A1 (en) Derivatives of 11-acetyl-12,13-dioxabicyclo[8.2.1]tridecenone, method of obtaining them and drugs containing such compounds

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20191206